Generics Adcock Ingram (AIP: SP), one of South Africa's largest drugmakers, has provided further details of the previously-announced proposed acquisition by Chile-based CFR Pharmaceuticals (The Pharma Letter July 4), saying that the boards of both companies have reached agreement regarding the proposed terms and conditions of the potential offer, worth around 12.6 billion rand ($1.26 billion) is to be settled partly in cash and partly in new CFR shares. 12 September 2013